Scarica l'app Stockscreener
17.98
1.41%
0.25
Dopo l'orario di chiusura:
17.85
-0.13
-0.72%
Precedente Chiudi:
$17.73
Aprire:
$17.29
Volume 24 ore:
58,789
Relative Volume:
3.44
Capitalizzazione di mercato:
$1.23B
Reddito:
$277.56M
Utile/perdita netta:
$-13.33M
Rapporto P/E:
-94.63
EPS:
-0.19
Flusso di cassa netto:
$-6.54M
1 W Prestazione:
+7.34%
1M Prestazione:
+4.84%
6M Prestazione:
+55.47%
1 anno Prestazione:
+92.92%
Intervallo 1D:
$17.18
$18.12
Intervallo di 1 settimana:
$16.68
$18.12
Portata 52W:
$7.5018
$18.12
Pharming Group N V Adr Stock (PHAR) Company Profile
Nome
Pharming Group N V Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PHAR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group N V Adr
|
17.98 | 1.21B | 277.56M | -13.33M | -6.54M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharming Group N V Adr Stock (PHAR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-09 | Iniziato | Jefferies | Buy |
Pharming Group N V Adr Borsa (PHAR) Ultime notizie
Pharming Group (NASDAQ:PHAR) Hits New 12-Month HighShould You Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Operating expenses (excl. COGS) of Pharming Group NV Sponsored ADR – LSX:A2QLQY - TradingView
Pharming Group (NASDAQ:PHAR) Stock Price Up 11%Time to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's Why - MarketBeat
Pharming Group (NASDAQ:PHAR) Sets New 12-Month HighStill a Buy? - MarketBeat
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade - MSN
Pharming Group (NASDAQ:PHAR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Up 8.6%Time to Buy? - MarketBeat
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? - MSN
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect? - sharewise.com
FY2025 EPS Estimates for Pharming Group Raised by Analyst - Defense World
Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase After Better-Than-Expected Earnings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group (PHAR) to Release Earnings on Thursday - Defense World
Pharming Group (NASDAQ:PHAR) Upgraded at Weiss Ratings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Up 9.5%What's Next? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 71.8% in September - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 64.2% - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.6%What's Next? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Up 7%Still a Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Finviz
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Still a Buy? - Defense World
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.4%What's Next? - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 378.6% - MarketBeat
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Stock Price Up 5%Here's Why - MarketBeat
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Zacks Investment Research
Pharming Group appoints Kenneth Lynard as Chief Financial Officer - GlobeNewswire Inc.
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Should You Buy? - Defense World
Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? - ca.finance.yahoo.com
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet - Yahoo Finance
Pharming Group N V Adr Azioni (PHAR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):